Roche

Swiss diversified pharma. Carmot acquisition (December 2023, $2.7B) brought CT-388 (about 23% placebo-adjusted weight loss at 48 weeks Phase 2), CT-996 oral, and CT-868. Zealand licensing deal ($1.65B) added petrelinitide amylin program.